溶酶体铁的激活会在癌症中引发铁
Tatiana Cañeque1, Leeroy Baron1, Sebastian Müller1
1Institut Curie, CNRS, INSERM, PSL Research University, Paris, France.
Nature
|May 7, 2025
概括
研究人员发现, 化体中的铁可以诱导细胞死亡的一种形式. 这一发现为癌症提供了新的治疗策略,
科学领域:
- 生物化学
- 细胞生物学
- 癌症治疗方法
背景情况:
- 铁催化细胞膜中的脂质氧化,导致铁.
- 了解由铁驱动的脂质氧化的细胞位置是开发ferroptosis调节药物的关键.
- 溶酶体参与铁,但它们在铁中介脂质氧化中的特定作用需要进一步定义.
研究的目的:
- 调查溶酶体在铁症中的作用.
- 确定可以调节溶酶体铁活性以获得治疗效益的小分子.
- 探索向溶酶体铁在癌症治疗中的潜力,特别是在耐药和转移性细胞中.
主要方法:
- 利用遗传和小分子方法研究铁.
- 研究铁抑制剂liproxstatin-1和诱导RSL3对细胞铁和脂质氧化的影响.
- 设计和合成了一种新型的小分子激活剂,称为芬托米辛-1.
- 在各种癌细胞系 (肉瘤,胰腺管腺癌) 和乳腺癌转移的小鼠模型中评估了芬托米辛- 1的疗效.
主要成果:
- 铁酶抑制剂liproxstatin-1通过激活溶酶体内的铁而起作用.
- 铁灭诱导剂RSL3触发了源自溶酶体的膜脂氧化.
- 芬托米辛-1 有效诱导氧化脂降解和铁,特别是在富含铁的CD44高瘤和胰腺癌细胞中.
- 通过降低介质标志物调节和激活膜损伤反应,用亚致死的芬托米辛-1 治疗的肉瘤细胞产生了耐药性.
- 在临床前的转移模型中,芬托米辛-1 证明有效地消除耐药的持续性癌细胞,并减少瘤生长.
结论:
- 溶酶体铁是诱导铁的可用药物目标,并提供治疗效益.
- 控制溶酶体中的铁反应性为癌症治疗提供了一个有前途的策略.
- 针对特定的细胞状态,如耐药性持续性细胞, 是一种有价值的治疗方法.
相关概念视频
01:16Necrosis
4.4K
Necrosis is considered as an “accidental” or unexpected form of cell death that ends in cell lysis. The first noticeable mention of “necrosis” was in 1859 when Rudolf Virchow used this term to describe advanced tissue breakdown in his compilation titled “Cell Pathology”.
Morphological Manifestations of Necrosis
Necrotic cells show different types of morphological appearance depending on the type of tissue and infection. In coagulative necrosis, cells become...
Morphological Manifestations of Necrosis
Necrotic cells show different types of morphological appearance depending on the type of tissue and infection. In coagulative necrosis, cells become...
4.4K
01:22Lysosomal Hydrolases
3.8K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
3.8K
01:28The Early Endosome: Endocytosis of Transferrin
3.3K
Essential proteins such as insulin or low-density lipoprotein (LDL) and micronutrients such as iron enter a eukaryotic cell through receptor-mediated endocytosis. Subsequently, the early endosomes fuse with the vesicles containing such receptor-ligand complexes and play a vital role in sorting the incoming ligands and receptors. While the ligands are either degraded inside the vesicle or released into the cytosol, their receptors are returned to the plasma membrane for further rounds of...
3.3K
02:57Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
01:31The Intrinsic Apoptotic Pathway
6.4K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.4K
01:30Overview of Cell Death
7.1K
Cell death is an essential process where the body gets rid of old or damaged cells. Cell proliferation and death need to be balanced, as an imbalance between the two may lead to cancer or autoimmune diseases.
Cell death was observed in the early 19th century, but there was no experimental evidence to prove it. In 1842, Carl Vogt first discovered cell death in a metamorphic toad; however, it was not termed ‘cell death.’ Scientists discovered different cell death pathways only in the...
Cell death was observed in the early 19th century, but there was no experimental evidence to prove it. In 1842, Carl Vogt first discovered cell death in a metamorphic toad; however, it was not termed ‘cell death.’ Scientists discovered different cell death pathways only in the...
7.1K